$SRTS

Sensus Healthcare, Inc.

CIK:0001494891|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF LOSS (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues	$ 2,290	$ 7,315	$ 5,684	$ 15,659
Cost of sales	1,521	4,412	3,924	8,403
Gross profit	769	2,903	1,760	7,256
Operating expenses
General and administrative	1,786	1,986	3,827	4,193
Selling and marketing	1,054	1,389	2,771	3,575
Research and development	1,109	1,471	2,699	4,077
Total operating expenses	3,949	4,846	9,297	11,845
Loss from operations	(3,180)	(1,943)	(7,537)	(4,589)
Other income:
Interest income, net	117	183	241	367
Other income, net	117	183	241	367
Loss before income tax	(3,063)	(1,760)	(7,296)	(4,222)
Provision for (benefit from) income taxes	5,686	(723)	4,079	(613)
Net loss	$ (8,749)	$ (1,037)	$ (11,375)	$ (3,609)
Net loss per share – basic	$ (0.53)	$ (0.06)	$ (0.69)	$ (0.22)
Net loss per share - diluted	$ (0.53)	$ (0.06)	$ (0.69)	$ (0.22)
Weighted average number of shares used in computing net loss per share - basic	16,462,059	16,320,036	16,462,355	16,330,891
Weighted average number of shares used in computing net loss per share - diluted	16,462,059	16,320,036	16,462,355	16,330,891

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (11,375)	$ (3,609)
Adjustments to reconcile net loss to net cash, restricted cash, and cash equivalents (used in) provided by operating activities:
Depreciation	182	185
Amortization of right-of-use asset	123	118
Provision for product warranties	134	138
Stock-based compensation	140	146
Deferred income taxes	4,079	(613)
Changes in operating assets and liabilities:
Accounts receivable	4,361	7,109
Inventories	(4,839)	(3,176)
Prepaid inventory	915	666
Other current assets	(62)	(842)
Other noncurrent assets	135	117
Accounts payable and accrued expenses	(176)	554
Operating lease liability	(128)	(118)
Deferred revenue	(233)	(35)
Product warranties	(142)	(200)
Net cash (used in) provided by operating activities	(6,886)	440
Cash flows from investing activities
Acquisition of property and equipment	(11)	(34)
Net cash used in investing activities	(11)	(34)
Cash flows from financing activities
Repurchase of common stock		(300)
Net cash used in financing activities		(300)
Net (decrease) increase in cash, restricted cash, and cash equivalents	(6,897)	106
Cash, restricted cash, and cash equivalents – beginning of period	22,083	22,056
Cash, restricted cash, and cash equivalents – end of period	15,186	22,162
Supplemental disclosure of cash flow information:
Interest paid
Income tax paid	8	979
Supplemental schedule of noncash investing and financing transactions:
Transfer of inventory to property and equipment	943	868
Lease liability arising from obtaining right-of-use-assets		$ 111

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash, restricted cash, and cash equivalents	$ 15,186	$ 22,083
Accounts receivable, net	1,680	6,041
Inventories	18,459	14,563
Prepaid inventory	607	1,522
Other current assets	1,745	1,683
Total current assets	37,677	45,892
Property and equipment, net	2,748	1,976
Deferred tax asset		4,079
Operating lease right-of-use assets, net	329	452
Other noncurrent assets	505	640
Total assets	41,259	53,039
Current liabilities
Accounts payable and accrued expenses	3,167	3,343
Product warranties	267	275
Operating lease liabilities, current portion	274	262
Deferred revenue, current portion	619	842
Total current liabilities	4,327	4,722
Operating lease liabilities	69	209
Deferred revenue, net of current portion		10
Total liabilities	4,396	4,941
Commitments and contingencies
Stockholders’ equity
Preferred stock, 5,000,000 shares authorized and none issued and outstanding
Common stock, $0.01 par value – 50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at June 30, 2026; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025	169	169
Additional paid-in capital	46,230	46,090
Treasury stock, 593,036 shares at cost, at June 30, 2026 and December 31, 2025	(3,876)	(3,876)
(Accumulated deficit) retained earnings	(5,660)	5,715
Total stockholders’ equity	36,863	48,098
Total liabilities and stockholders’ equity	$ 41,259	$ 53,039